Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Sponsor: RVL Pharmaceuticals, Inc.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral arbaclofen ER tablets in MS patients with spasticity. Arbaclofen ER will be compared with placebo.
Official title: A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
442
Start Date
2027-01
Completion Date
2028-04
Last Updated
2025-12-03
Healthy Volunteers
No
Conditions
Interventions
Arbaclofen
Arbaclofen Extended Release Tablets
Placebo
Placebo tablets